This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. From bionic eyes to cell and gene therapies in clinical trials, it's an exciting time for ...
Wed, March 11, 2026 at 2:23 PM UTC Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy ...
Hosted on MSN
New laser treatment could stop blindness even before it starts and restore early eye health
For millions across the world, blindness often begins quietly, with gradual retinal damage that goes unnoticed until it is too late. Now, a new scientific breakthrough could change that future.
Please provide your email address to receive an email when new articles are posted on . RTx-015 optogenetic gene therapy is designed to restore vision by “reprogramming” retinal cells. The designation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results